

 \mathbb{N}

levana@nalagenetics.com

+62 817 9130 787

www.nalagenetics.com





CHARITÉ/BIH-PARTNER WANTED!

Short profile Name: Nalagenetics

Medical fieldCancerProduct typeMedical Devices, Diagnostics, and TherapeuticsGrowth stagePositioning for ScaleTeam23 people

Description of product:

MammoReady[™] is a DNA test to help patients understand their risks of developing breast cancer in the next 5 years based on three key risk analyses: monogenic, polygenic and clinical risk models. The test report also comes with actionable recommendations extracted form established guidelines.

Desired project goal: Please also elaborate on the primary outcome

Test-bedding of MammoReady[™] as a risk stratification solution for breast cancer, with the project scope of (a) clinical validation, (b) pilot study and (c) cost-effectiveness study.

- (a) Validation of MammoReady[™]'s risk prediction model with application of several testing criteria, such as risk model discrimination and risk model predictive ability.
- (b) Pilot study (randomized clinical trial) mirroring GenoVA study in the US to assess clinical utility of MammoReady[™] as a personalized risk screening tool compared to current standard of care.
- (c) Cost-effectiveness study of integrating MamomReady[™] in the patient journey from the societal, payor and health sector perspectives compared to current standard of care.

Desired project type: Please also elaborate on the following points, if applicable: population, intervention, study design etc.

Test bedding and validation.

DR. HANA HASTOR, Medical Advisor CSC (CRU) <u>hana.hastor@bih-charite.de</u>